← Leaderboards
Gregory L Beatty
University Of Pennsylvania
$6,306,069
Attributed
$6,560,004
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $893.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,560,004 · 6
By mechanism
R01$5,170,455 · 2
K08$812,310 · 1
T32$507,871 · 1
M01$69,368 · 2
Top collaborators
- Michael D Hogarty1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Mitchell A. Lazar$48,884,193
- Mark E Haskins$13,363,758
- Peter J. Snyder$40,848,094
- Ronen Marmorstein$40,497,435
- Leszek K Kubin$12,685,863
Others in their field
Top investigators on “Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Jeffrey P Krischer · University Of South Florida$62,791,489
- Klaus H. Kaestner · University Of Pennsylvania$51,057,263
- Anirban Maitra · Johns Hopkins University$43,666,915
- Charles A Coltman · Southwest Oncology Group$36,817,493
- Ali Naji · University Of Pennsylvania$30,540,599
Research focus
PancreasInterleukin-6Malignant NeoplasmsTumorHuman DiseaseShapesMouse ModelMolecularMacrophageVariantAgonistMyeloid CellsTnfrsf5 GeneImmunologicsNovel TherapeuticsCytotoxic ChemotherapySignal PathwayStat3 GeneCellsGeneticChemotherapyClinically RelevantPancreatic Ductal AdenocarcinomaImmunotherapy
Grant awards (23)
Cancer Center Research Training Program$507,871
T32 · FY2025 · CA
Targeting the liver for immunotherapy in pancreatic cancer$385,938
R01 · FY2025 · CA · contact PI
Targeting the liver for immunotherapy in pancreatic cancer$366,641
R01 · FY2024 · CA · contact PI
Mechanisms and therapeutic targets of cancer metastasis$353,134
R01 · FY2024 · CA · contact PI
Targeting the liver for immunotherapy in pancreatic cancer$378,219
R01 · FY2023 · CA · contact PI
Mechanisms and therapeutic targets of cancer metastasis$364,284
R01 · FY2023 · CA · contact PI
Targeting the liver for immunotherapy in pancreatic cancer$385,938
R01 · FY2022 · CA · contact PI
Mechanisms and therapeutic targets of cancer metastasis$364,284
R01 · FY2022 · CA · contact PI
Mechanisms and therapeutic targets of cancer metastasis$371,052
R01 · FY2021 · CA · contact PI
Mechanisms and therapeutic targets of cancer metastasis$370,575
R01 · FY2020 · CA · contact PI
Targeting macrophages for immunotherapy in pancreatic cancer$368,288
R01 · FY2020 · CA · contact PI
Targeting macrophages for immunotherapy in pancreatic cancer$357,238
R01 · FY2019 · CA · contact PI
Targeting macrophages for immunotherapy in pancreatic cancer$368,288
R01 · FY2018 · CA · contact PI
Targeting macrophages for immunotherapy in pancreatic cancer$368,288
R01 · FY2017 · CA · contact PI
Targeting macrophages for immunotherapy in pancreatic cancer$368,288
R01 · FY2016 · CA · contact PI
CD40 Pathway in Pancreatic Adenocarcinoma$162,462
K08 · FY2015 · CA · contact PI
CD40 Pathway in Pancreatic Adenocarcinoma$162,462
K08 · FY2014 · CA · contact PI
CD40 Pathway in Pancreatic Adenocarcinoma$162,462
K08 · FY2013 · CA · contact PI
CD40 Pathway in Pancreatic Adenocarcinoma$162,462
K08 · FY2012 · CA · contact PI
CD40 Pathway in Pancreatic Adenocarcinoma$162,462
K08 · FY2011 · CA · contact PI
SEMINAL FLUID HIV EVOLUTION IN PATIENTS EXPERIENCING PARTIAL VIRAL SUPPRESSION$53,822
M01 · FY2005 · RR
Dietary intervention in HIV and insulin resistance$8,182
M01 · FY2004 · RR
SEMINAL FLUID HIV EVOLUTION IN PATIENTS EXPERIENCING PARTIAL VIRAL SUPRESSION$7,364
M01 · FY2004 · RR